Key Drivers
- High margins
- Weak liquidity
- Negative cash flow
AIAI Summary
INDV has clearly moved past the “turnaround” phase, with strong SUBLOCADE-driven revenue and EBITDA growth, but the investment now hinges on proving that this momentum can convert into sustained free cash flow and a sturdier balance sheet rather than just a rerated earnings story.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Weak liquidity
- •Negative cash flow
INDV is generating strong margins and earnings growth, but its weak balance sheet, negative free cash flow, and rising leverage keep the investment case risky despite decent valuation support.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Support holding
- •Momentum cooling
INDV remained technically constructive last month after climbing from the low $30s to above $40, but the pullback to $36.76 and lower highs since May 6 show momentum has cooled and it must reclaim $39.50-$40.60 to resume strength.
Briefly broke above $40.00 on 2026-05-06 before sliding back to $36.76
Sentiment & News
Key News Insights:
- •Revenue growth
- •Share repurchase
- •Sentiment improving
Indivior's latest updates point to strong operating momentum, a raised 2026 outlook, a $175M buyback, and improving investor sentiment backed by supportive clinical and technical signals.
The news is broadly positive for Indivior, suggesting stronger near-term upside potential as fundamentals, capital returns, and market sentiment all improve
Similar Companies in Healthcare
Other companies in the same sector with AI ratings